COMPOUNDS AND METHODS TO TREAT ORGANOPHOSPHORUS POISONING
申请人:University of Iowa Research Foundation
公开号:US20140323473A1
公开(公告)日:2014-10-30
Organophosphate (OP) nerve agents and pesticides are potent inhibitors of acetylcholinesterase (AChE). Though oxime nucleophiles can reactivate an AChE-phosphyl adduct, the adduct can undergo a reaction called aging, leading to an aged-AChE adduct. The invention provides compounds and methods that can be used to reactivate an aged-AChE adduct. Such compounds and methods are useful to counteract organophosphorus poisoning.
The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.
The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.
[EN] CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (BCHE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM<br/>[FR] PIÉGEURS CATALYTIQUES D'ORGANOPHOSPHATES POUR POTENTIALISER LA BUTYRYLCHOLINESTÉRASE (HBCHE)
申请人:UNIV CALIFORNIA
公开号:WO2015057822A1
公开(公告)日:2015-04-23
Provided are N-alkyl imidazole 2-aldoximes, including cationic imidazolium and uncharged tertiary imidazole aldoximes, and compositions and methods for making and using them, including methods for reactivating human butyrylcholinesterase (hBChE) or acetylcholinesterase (hAChE ) inhibited by organophosphate (OP). By administration of a composition of the invention, the inactive or conjugated hBChE-OP or hAChE-OP is reactivated and the catalytic cycle of turnover and inactivation of the OP is completed; and in alternative embodiments, secondary mechanisms of reversible protection of hBChE and hAChE from irreversible inactivation by OPs and reactivation of tissue AChE also contribute to overall efficacy.
[EN] DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES<br/>[FR] DÉRIVÉS DE GALANTAMINE COMME PROMÉDICAMENTS POUR LE TRAITEMENT DE MALADIES DU CERVEAU HUMAIN
申请人:GALANTOS PHARMA GMBH
公开号:WO2009127218A1
公开(公告)日:2009-10-22
The present invention refers to selected galantamine derivatives having high efficacy in treatment of human brain diseases and low side effects.